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Abstract
Oncolytic adenoviral mutants infect human malignant cells and replicate selectively within them. This induces direct
cytotoxicity that can also trigger profound innate and adaptive immune responses. However, the mechanism by
which adenoviruses produce cell death remains uncertain. We previously suggested that type 5 adenoviruses,
including the E1A CR2 deletion mutant dl922-947, might induce a novel form of programmed death resembling
necroptosis. Here we have investigated the roles of core necrosis proteins RIPK1, RIPK3 and MLKL in the cytotoxicity of
dl922-947 and other adenovirus serotypes. By electron microscopy, we show that dl922-947 induces similar necrotic
morphology as TSZ treatment (TNF-α, Smac mimetic, zVAD.fmk). However, dl922-947-mediated death is independent
of TNF-α signalling, does not require RIPK1 and does not rely upon the presence of MLKL. However, inhibition of
caspases, speciﬁcally caspase-8, induces necroptosis that is RIPK3 dependent and signiﬁcantly enhances dl922-947
cytotoxicity. Moreover, using CRISPR/Cas9 gene editing, we demonstrate that the increase in cytotoxicity seen upon
caspase inhibition is also MLKL dependent. Even in the absence of caspase inhibition, RIPK3 expression promotes
dl922-947 and wild-type adenovirus type 5 efﬁcacy both in vitro and in vivo. Together, these results suggest that
adenovirus induces a form of programmed necrosis that differs from classical TSZ necroptosis.
Introduction
Oncolytic viruses are a promising new therapy for
cancer. They can infect cancer cells, multiply selectively
within them and cause cell death, with release of mature
viral particles that infect neighbouring cells. We have
previously shown that the E1A CR2-deleted adenovirus
type 5 mutant dl922-947 has considerable activity in
ovarian cancer and is more potent than both E1A wild-
type adenoviruses and the E1B-55K mutant dl1520
(Onyx-015)1,2. We have also shown that dl922-947
induces robust DNA double-strand break damage in
infected cells3 and utilises components of the homologous
recombination pathway to promote efﬁcacy4.
The exact mechanisms by which adenoviruses cause cell
death remain uncertain. We previously showed that classi-
cal apoptosis is not the primary mode of cell death following
E1A CR2-deleted adenovirus infection in ovarian cancer
and that autophagy was likely to be a survival mechanism5.
Our overall conclusion was that adenovirus cytotoxicity
had the features of a programmed necrotic process.
Necrosis is now realised to be a highly regulated form of
cell death6. The best-characterised pathway of pro-
grammed necrosis (or necroptosis) occurs when tumour
necrosis factor (TNF)-α (T) binds to TNFR1 in the pre-
sence of a Smac-mimetic (S) and the pan-caspase inhi-
bitor zVAD.fmk (Z). The critical step in TSZ-induced
necroptosis is the formation of the necrosome, a complex
that includes RIPK1 and RIPK3, both of which contain
RHIM (RIP homotypic interaction motif) domains. Mixed
lineage kinase domain-like (MLKL) then binds to RIPK3
through its C-terminal kinase-like domain, which is
phosphorylated at T357/S358 by RIPK3, leading to its
activation and translocation to the cell membrane, where
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it is involved in the formation of pores, ion inﬂux and
membrane disruption7,8. Other pathways of programmed
necrotic death exist that are independent of the TNF-α/
TNFR interaction—Tenev et al. and Feoktiskova et al.
described the ripoptosome, a death-inducing complex
that forms upon genotoxic stress and that leads to
caspase-dependent apoptosis or caspase-independent
necrosis depending upon both cellular caspase-8 activ-
ity9,10 and the levels and cleavage state of cFLIP (reviewed
in ref.11). Similarly, necrosome-like complexes can also
form as a result of Toll-like receptor (TLR) signalling12 in
response to lipopolysaccharide13 and poly(I:C)14. In
addition, RIPK3 can induce necrosis independently of
RIPK1 and MLKL; for example, following ischaemia/
reperfusion injury or doxorubicin treatment, RIPK3
induces necrotic death in cardiac myocytes by binding
directly to and activating CaMKII (calcium-calmodulin-
dependent protein kinase)15.
Multiple viruses trigger RIPK1/RIPK3-dependent
responses, including vaccinia16,17, murine cytomegalo-
virus18 and inﬂuenza A19. In herpes simplex virus (HSV)-1
infection, ICP6 binds to RIPK1/RIPK3 in both human and
murine cells, which triggers a necrotic response in
mouse20 but suppresses necrosis in human cells21.
Here we have investigated the roles of RIPK1, RIPK3
and MLKL in the cytotoxicity of dl922-947 and other
adenovirus serotypes. We show that adenovirus induces
similar necrotic morphology to TSZ. However, cytotoxi-
city is independent of TNF-α signalling and RIPK1 and
does not rely upon the presence of MLKL. RIPK3
expression augments adenovirus efﬁcacy, while caspase-8
inhibition can signiﬁcantly enhance activity in a RIPK3-
and MLKL-dependent manner. These results suggest that
adenovirus induces a form of programmed necrosis that
differs from classical TSZ necroptosis.
Results
Induction of necroptosis in tumour cells
We ﬁrst investigated the expression of RIPK1, RIPK3,
caspase-8 and MLKL in a panel of ovarian cancer cell
lines as well as HeLa cells (Fig. 1a). Only TOV21G cells
expressed all three proteins in equal quantities and were
sensitive to necroptosis induced by TSZ (TNF-α, Smac
mimetic, zVAD.fmk) that was reversible by treatment
with necrostatin-1 and necrosulphonamide (NSA)
(Fig. 1b). We evaluated the sensitivity of TOV21G and
two TSZ-resistant lines, OVCAR4 and HeLa, to the E1A
CR2-deleted Ad5 vector dl922-947 as well as wild-type
adenovirus of different serotypes (Fig. 1c). As we have
noted previously22, TOV21G was consistently the most
sensitive line. By electron microscopy, the morphology of
dl922-947-treated cells was similar to morphology of
those treated with TSZ, with swollen mitochondria,
cytoplasmic disintegration and loss of membrane integrity
(Fig. 1d, Fig. S1), in keeping with a necrotic process. In
addition, assessment by ﬂow cytometry with a membrane-
impermeable ﬂuorescent dye showed progressive loss of
membrane integrity following dl922-947 infection in both
TOV21G and OVCAR4 cells (Fig. S2)
dl922-947-induced necrosis does not result from local
TNF-α production nor is RIPK1 involved
Infection with dl922-947 was not associated with
marked changes in the expression of RIPK1, RIPK3, MLKL
(Fig. 2a) or caspase-8 (Fig. S3). Inhibition of TNF-α using a
blocking antibody had no effect on dl922-947 activity
(Fig. 2b), while treatment with necrostatin-1 (Fig. 2c,
Fig. S4) and the RIPK1 inhibitors GSK3002962A and
GSK3002963A (Fig. 2d, Fig. S5) also had no effect on virus
efﬁcacy. Finally, small interfering RNA (siRNA)-mediated
RIPK1 knockdown also did not inhibit dl922-947 activity
(Fig. 2e). Thus we conclude that virus-induced death does
not rely upon either TNF-α or RIPK1.
MLKL is not an absolute requirement for dl922-947-
induced cytotoxicity
MLKL is the critical ﬁnal mediator of necrotic cell death
following multiple stimuli, including TSZ treatment.
Following dl922-947 infection, we saw re-localisation of
MLKL from the nucleus to the cell membrane (Fig. 3a),
which is required for MLKL-induced necrosis23. Fur-
thermore, we saw a small but signiﬁcant and dose-
dependent inhibition of dl922-947 activity following
treatment with the MLKL inhibitor NSA that was similar
in both TSZ-sensitive TOV21G cells and TSZ-resistant
OVCAR4 (Fig. 3b). This initially suggested that MLKL
may be involved in dl922-947-mediated cell death.
However, we were unable to detect any MLKL phos-
phorylation following dl922-947 infection (Fig. 3c; see
also Fig. S14). In addition, siRNA-mediated MLKL
knockdown have no signiﬁcant effect on virus efﬁcacy but
completely abrogated TSZ cytotoxicity (Fig. 3d). We
therefore concluded that MLKL is not an absolute
requirement for the death induced by adenovirus type 5.
RIPK3 expression augments efﬁcacy in vitro
We focussed next upon RIPK3, a critical kinase in both
apoptosis and necrotic cell death. Following retroviral
transduction, we generated a series of HeLa clones
expressing RIPK3 (Fig. 4a, Fig. S6). Expression of RIPK3
increased sensitivity to TSZ, which was reversible by NSA
treatment (Fig. 4a). These RIPK3 clones were also sig-
niﬁcantly more sensitive to cytotoxicity mediated by
dl922-947 (Fig. 4b, Fig. S7) and Ad5 wild type (Fig. S8),
although not by Ad11p (Fig. S9). Sensitivity to dl922-947
correlated signiﬁcantly with the extent of RIPK3 expres-
sion (Fig. 4c) and was not affected by treatment with NSA
(Fig. 4d) or RIPK1 inhibition (Fig. S10). However,
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sensitivity was reversed by the RIPK3 inhibitor
GSK2791840B (Fig. 4e, Fig. S5). Expression of RIPK3 did
not alter the expression of other core necrosis proteins
(Fig. 4f) nor did it increase viral protein expression or viral
replication (Fig. 4g). However, siRNA-mediated RIPK3
knockdown in TOV21G cells signiﬁcantly reduced viral
cytotoxicity as well as TSZ-induced death (Fig. 4h),
Together, these results suggest that RIPK3 activity can
augment efﬁcacy of adenoviruses. Double siRNA for
RIPK1 and RIPK3 in TOV21G cells induced signiﬁcant
toxicity (data not shown), so it was not possible to assess
whether loss of both kinases inﬂuenced viral activity.
RIPK3 expression improves in vivo efﬁcacy
We then evaluated the effect of RIPK3 expression
in vivo. We ﬁrst conﬁrmed that RIPK3 expression did not
alter growth of subcutaneous xenografts from two HeLa
RIPK3 clones, D2 and E4 (Fig. 5a), and that RIPK3
expression was maintained in vivo (Fig. 5b). Expression of
E1A and adenovirus structural proteins was assessed
using quantitative immunohistochemistry (IHC) in con-
trol (HeLa LZRS) and RIPK3-expressing tumours fol-
lowing a single intratumoural injection of dl922-947. As
with the in vitro data, there was no difference in viral
protein expression (Fig. 5c), but we did detect a signiﬁcant
increase in total necrotic area in RIPK3-expressing
tumours following dl922-947 injection compared to
HeLa LZRS (Fig. 5d). In a therapeutic experiment using
the HeLa-RIPK3 D2 clone, RIPK3 expression signiﬁcantly
enhanced the activity of intratumoural dl922-947 (Fig. 5e,
Fig. S11), with complete elimination of 3/6 HeLa-RIPK3
D2 tumours compared to 0/6 HeLa-LZRS tumours.
Caspase-8 inhibition augments viral cytotoxicity that is
reversed by RIPK3 inhibition and MLKL knockout
Finally, we sought to explain how RIPK3 inﬂuences
adenovirus activity. Previously, we showed that zVAD.
fmk, the pan-caspase inhibitor, does not reverse dl922-
947 efﬁcacy in multiple ovarian cancer cells5, including
OVCAR4, which we re-conﬁrmed here (Fig. S12). How-
ever, we observed here that addition of 25 µM zVAD.fmk
consistently and signiﬁcantly increased the activity of
dl922-947 (Fig. 6a) and Ad5 (Fig. S13) in TOV21G.
Moreover, this effect was recapitulated following
treatment of TOV21G with the caspase-8-directed inhi-
bitor zIETD.fmk (25 µM) (Fig. 6b). There was clear evi-
dence of MLKL phosphorylation 72 h following dl922-947
infection in the presence of zVAD.fmk (Fig. 6c) but not at
24 or 48 h (Fig. S14), and the effect of zVAD.fmk was
partially rescued by the RIPK3 inhibitor GSK2791840B
(Fig. 6d). To explore further, we performed RIPK3
co-immunoprecipitation and demonstrated an interaction
between RIPK3 and MLKL following dl922-947 infection
(Fig. 6e, Fig. S15) as well as an interaction between RIPK3
and adenovirus proteins (Fig. 6f). We then used CRISPR/
Cas9 gene editing to knock out MLKL in TOV21G cells.
We were unable to isolate any clones with bi-allelic
mutations in MLKL but did identify three heterozygote
clones (Supplementary data) with reduced MLKL
expression by immunoblot and reduced sensitivity to
TSZ-induced necrosis compared to both parental
TOV21G cells and clones with no MLKL mutations
(Fig. 6g). The partial loss of MLKL did not increase sen-
sitivity to dl922-947 signiﬁcantly (Fig. 6h), in keeping with
siRNA experiments (Fig. 3d), but completely reversed the
zVAD.fmk-mediated increase in dl922-947 efﬁcacy
(Fig. 6i).
Discussion
Evasion of cell death is a hallmark of cancer24, and all
anticancer therapies must circumvent these death-
resistance mechanisms to be effective. Oncolytic viruses
are a novel form of therapy that can both induce direct
cytotoxicity in infected cells and establish adaptive anti-
tumour immune responses25. However, the mode of death
induced by adenovirus remains unclear.
We previously showed that E1A CR2-deleted serotype 5
adenoviruses induce a form of programmed death that
was not apoptotic but had features to suggest a type of
necrosis5. However, there have been few attempts to
interrogate adenovirus-induced cell death since the recent
elucidation of programmed necrosis pathways. Our
results here indicate that the group C adenoviruses dl922-
947 and Ad5 wild type induce a mode of cell death that
morphologically appears necrotic with associated mem-
brane rupture. We show that these viruses do not require
the necrotic kinase RIPK1 and that blockade of TNF-α
does not inhibit viral activity. Although NSA treatment
(see ﬁgure on previous page)
Fig. 1 Induction of necrosis in ovarian cancer cells. a Expression of RIPK1, RIPK3, caspase-8 and MLKL was assessed in ovarian cancer cells and
HeLa by immunoblot. b OVCAR4, TOV21G and HeLa cells were treated with TNF-α (T, 20 ng/ml), the Smac-mimetic LCL-161 (S, 1 μM) and/or zVAD.
fmk (Z, 25 µM) for 6 h in the presence and absence of necrostatin-1 (Nec, 10 µM) and necrosulfonamide (NSA, 1 µM). Arrows indicate necrosis
induced by TSZ in TOV21G cells, reversed by Nec and NSA. Cell survival was assessed by MTT assay. c OVCAR4, TOV21G and HeLa cells were infected
with dl922-947, Ad5, Ad35 and Ad11p (MOI 0.01–1000 pfu/cell) for 120 h. Cell survival was assessed by MTT assay. d Transmission electron
microscopic images of TOV21G cells following 6 h treatment with TSZ (concentrations as 1B) or 48 h infection with dl922-947 (MOI 1). White arrows
indicate sites of membrane rupture; black arrows indicate electron-dense mitochondria
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Fig. 2 RIPK1 plays no role in dl922-947-induced cytotoxicity. a Expression of core necrosis proteins RIPK1, RIPK3 and MLKL following dl922-947
infection was assessed in OVCAR4 (MOI 10) and TOV21G (MOI 1) cells. b OVCAR4 and TOV21G cells were infected with dl922-947 in the presence and
absence of blocking anti-TNF-α Ab (1 µg/ml). Cell survival was assessed after 120 h by MTT assay. c Necrostatin-1 (10 µM) treatment has no effect on
dl922-947 cytotoxicity in OVCAR4 and TOV21G cells. Each dot represents IC50 from a single triplicate experiment. d OVCAR4 and TOV21G cells were
infected with dl922-947 in the presence and absence of blocking RIPK1 inhibitors GSK3002962A and GSK2003963A (both 10 nM). Cell survival was
assessed after 120 h by MTT assay. e RIPK1 knockdown in TOV21G cells (left) 24 h following transfection with 10–100 pmol siRNA. 10 pmol
RIPK1 siRNA signiﬁcantly reduced TSZ-induced cell death. Adenovirus cytotoxicity experiments (right) utilised 10 pmol siRNA. Cells were infected with
dl922-947 24 h following siRNA transfection. Cell survival was assessed 120 h thereafter
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partially inhibited cytotoxicity in a dose-dependent man-
ner in TOV21G and OVCAR4 cells, suggesting that
MLKL might play a role, siRNA experiments were nega-
tive (Fig. 3d), NSA treatment had no effect in the HeLa-
RIPK3 clones and there was no MLKL phosphorylation at
24 and 48 h hours postinfection (Fig. S14), implying that
the NSA effect represented off-target activity. By contrast,
RIPK3 does play a role, with reduction in cytotoxicity
upon siRNA-mediated knockdown in TOV21G cells and
increased cell death both in vitro and in vivo upon RIPK3
overexpression in HeLa. Moreover, we also show that
inhibition of caspases, speciﬁcally caspase-8, signiﬁcantly
augments activity in necrosis-competent TOV21G cells,
in a manner that is RIPK3 and MLKL dependent.
Fig. 3 MLKL is not essential for dl922-947-induced cytotoxicity. a MLKL relocalises to the plasma membrane in TOV21G following dl922-947
infection (MOI 1, 48 h). b Necrosulphonamide (NSA) treatment signiﬁcantly inhibits dl922-947 cytotoxicity in OVCAR4 and TOV21G cells. Each dot
represents IC50 from a single triplicate experiment. NSA concentrations were 0, 3 and 10 µM. ***p < 0.001 for linear trend across NSA concentrations.
c MLKL phosphorylation was assessed in TOV21G cells following TSZ (6 h) or dl922-947 (MOI 1, 48 h) treatment by immunoblot. d MLKL knockdown
in TOV21G cells (left) up to 144 h following transfection with 10 pmol siRNA. Adenovirus and TSZ cytotoxicity experiments (right). Cells were treated
with TSZ or with dl922-947 24 h following siRNA transfection. Cell survival was assessed 6 h (TSZ) and 120 h (dl922-947) thereafter. ***p < 0.001
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The ﬁrst conclusion of these results is that group C
adenovirus-induced death differs from the classical
pathway of necroptosis induced by TSZ (TNF-α, Smac
mimetic and zVAD.fmk) and does not absolutely require
the presence of RIPK1, RIPK3 and MLKL; HeLa cells do
not express RIPK3, while OVCAR4 express low levels of
both RIPK3 and MLKL, and both are resistant to TSZ
treatment. Yet both still undergo cytotoxicity following
adenovirus infection (Fig. 1a–c). Nonetheless, TOV21G
cells, which are intrinsically TSZ sensitive, are the
most susceptible to adenovirus, as we have shown pre-
viously3,22, and siRNA-mediated RIPK3 knockdown par-
tially enhanced cytotoxicity in these cells. Furthermore,
HeLa-RIPK3 cells, which are rendered TSZ-sensitive
through RIPK3 expression, had increased adenovirus
sensitivity, with a direct correlation between extent of
RIPK3 expression and sensitivity. Together, these results
suggest a link between virus activity and programmed
necrosis.
The second conclusion is that adenovirus-induced
death parallels that induced by other DNA viruses,
including murine cytomegalovirus (mCMV). In mCMV
infection, RIPK1 is also redundant, and caspase-8 acts to
suppress RIPK3-mediated death18. In addition, the
mCMV M45 gene encodes viral inhibitor of RIP activa-
tion, which contains a RHIM domain and blocks RIPK3-
dependent death18. Here co-immunoprecipitation
experiments demonstrate that a RIPK3- and MLKL-
containing complex forms following dl922-947 infection
and that MLKL phosphorylation (and hence activation) is
evident upon caspase inhibition. Thus, in TOV21G cells,
caspase-8 acts to suppress virus-induced necrosis. Our
data are also intriguing in that, in the absence of caspase
inhibition, knockdown of RIPK3, but not MLKL, partially
reduces cytotoxicity (Fig. 4f), suggesting that there may be
other death effector proteins that are activated by RIPK3
in the presence of adenovirus infection. We hypothesise
that there are critical interactions between adenovirus
proteins and RIPK3 that inhibit RIPK3 function and thus
prevent MLKL phosphorylation in the absence of caspase-
8 inhibition. However, unlike mCMV and HSV-1, there
are no published reports of RHIM domain-containing
adenovirus proteins. Co-immunoprecipitation here did
suggest direct interaction between RIPK3 and adenovirus
capsid proteins, but further analysis will be required to
establish the speciﬁcity and signiﬁcance of these interac-
tions, as well as to identify other adenovirus proteins that
might bind to RIPK3.
It is known that adenovirus encodes proteins that can
speciﬁcally inhibit mitochondrial apoptosis, especially
E1B 19K, a Bcl2 homologue that blocks Bax homo/het-
erodimerisation26,27. Other adenovirus proteins involved
in cell death include E3 11.6K (adenovirus death protein,
ADP) and E4orf4. ADP is expressed late following infec-
tion and promotes lysis of infected cells28,29 and may be a
critical regulator of lytic versus latent infection in lym-
phocytes30. However, there are no publications to suggest
that ADP-mediated lysis might represent a necrotic pro-
cess nor that ADP interacts with RIPK3 or MLKL. E4orf4,
when expressed alone, can induce p53-independent,
caspase-independent cell death31,32, but again, there is no
evidence to support an interaction with any necrotic
proteins, nor indeed to support a role for E4orf4 in cell
death during productive adenovirus infection33.
Dyer et al. have recently investigated the group B ade-
novirus enadenotucirev (EnAd) in A549 cells34 and sug-
gested that, rather than a necrotic process, cytotoxicity
resembled ischaemic oncosis, a form of death marked by
ATP loss, a rise in intracellular calcium and loss of
membrane integrity with release of inﬂammatory media-
tors35. Some of the changes seen following EnAd infection
were replicated following Ad11p and Ad5 infection,
although they were less marked. Our data do not neces-
sarily contradict these results, as loss of ATP and mem-
brane integrity are also observed in necrosis36, including
that induced by vaccinia, as we have previously noted16.
Other viruses also interact with RIPK3, including
inﬂuenza A virus (IAV). IAV infection activates RIPK3,
(see ﬁgure on previous page)
Fig. 4 RIPK3 expression augments dl922-947-induced cytotoxicity in vitro. a Following retroviral transduction, HeLa-RIPK3 single-cell clones
were isolated. LZRS control clone was also isolated. RIPK3 expression (left) and sensitivity to NSA-reversible TSZ necrosis (right) were assessed. b HeLa-
RIPK3 clones were signiﬁcantly more sensitivity to dl922-947 than control LZRS. Each dot represents IC50 for each clone from a triplicate
dose–response experiment. *p < 0.05. c Correlation between RIPK3 expression and dl922-947 sensitivity. Relative RIPK3 expression was quantiﬁed in
HeLa-RIPK3 clones (red) and HeLa-LZRS cells (blue) from multiple immunoblots and correlated with dl922-947 IC50 values. d Treatment with 3 µM
NSA has no effect on dl922-947 efﬁcacy in HeLa-LZRS or HeLa-RIPK3 D2 cells. Each dot represents IC50 from a triplicate dose–response experiment.
e Treatment with speciﬁc RIPK3 inhibitor GSK2791840B (10 nM) inhibited dl922-947 cytotoxicity in HeLa-RIPK3 (clone D2) but not HeLa-LZRS.
f Expression of RIPK1, RIPK3, caspase-8 and MLKL was assessed in HeLa-LZRS and HeLa-RIPK3 D2 and E4 cells. g Expression of adenovirus proteins
(left) and generation of infectious virions (right) was not increased in HeLa-RIPK3 cells compared to Hela-LZRS. Adenovirus structural protein
nomenclature: II (hexon), III (penton base), IIIA, IV (ﬁber) and V (core). h RIPK3 knockdown in TOV21G cells (left) following transfection with 30 pmol
siRNA. Adenovirus and TSZ cytotoxicity experiments (right). Cells were treated with TSZ or with dl922-947 24 h following siRNA (30 pmol) transfection.
Cell survival was assessed 6 h (TSZ) and 120 h (dl922-947) thereafter. *p < 0.05. ***p < 0.001
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which then triggers parallel pathways of cell death,
including MLKL-dependent necrosis and FADD-
dependent apoptosis19. The key sensor for RIPK3 activa-
tion is DAI, which recognises IAV RNA37. Thus other
host proteins beyond the core necrotic machinery may be
responsible for directing cell death. It is noticeable that
the enhancement of dl922-947-induced cytotoxicity seen
in the presence of zVAD.fmk and zIETD.fmk in TOV21G
cells was not recapitulated in HeLa-RIPK3 cells (data not
shown) despite expression of caspase-8 in these cells,
suggesting the presence of speciﬁc pathways within
TOV21G cells responsible for these observations. Other
potential cellular pathways to trigger RIPK3 activation
include TLR signalling. Inhibition of caspase-8 in the
presence of activated TLR signalling, including TLR3 and
TLR4, results in RIPK3-dependent necrosis that requires
TRIF or MyD88 signalling12. It is certainly known that
adenovirus can activate multiple TLR signalling pathways,
including TLR438. Recent data also suggest that human
adenovirus uptake can induce very rapid necrosis of liver
macrophages that is independent of RIPK3 activity, but
relies upon the transcription factor IRF3 (interferon-reg-
ulatory factor 3), and is triggered by viral entry into the
cytosol39. However, the kinetics of liver macrophage
death, which was observed within 5–10min of intrave-
nous injection of human adenovirus into wild-type C57Bl/
6 mice, are dramatically different from that seen following
infection of human epithelial cells and occuring prior to
any viral gene expression. One difﬁculty of investigating
adenovirus-induced death in vivo is the species speciﬁcity
of human adenovirus. We have previously identiﬁed fail-
ure of translation of late human adenovirus mRNA in
murine cells as a key factor in that speciﬁcity40, which
precludes the use of transgenic murine models as tools to
investigate the role of speciﬁc host genes either in whole
animals of murine embryonic ﬁbroblasts. However, a
valuable lesson from the investigation of HSV-1 is that
host species is critical—the ICP6/RIPK3 interaction has
polar opposite effects in murine and human cells20,21—
implying strong evolutionary pressure in natural hosts to
protect against from virus infection41.
In summary (Fig. 7), we show here that group C
adenovirus-induced death has some hallmarks of necrosis
that differs from the classical TSZ-induced death and is
speciﬁcally independent of TNF-α and RIPK1. In the
presence of caspase-8 inhibition, death can proceed in a
RIPK3- and MLKL-dependent pathway. Future work will
be required to identify whether speciﬁc adenovirus pro-
teins regulate this effect and the key host signalling
pathways involved.
Materials and methods
Cell lines, viruses and viability assays
HeLa and 293T cells were obtained from Cancer
Research UK Cell Services (Clare Hall, UK), OVCAR4
from National Cancer Institute (Frederick, MA, USA) and
TOV21G from Professor Fran Balkwill (Barts Cancer
Institute, London, UK). The Phoenix-AMPHO cells were
kindly provided by Stephen Tait’s laboratory. Cells were
cultured in Dulbecco’s Modiﬁed Eagle Medium with 10%
heat-inactivated foetal bovine serum, 2 mM L-Glutamine,
100 units/ml penicillin and 100 μg/ml streptomycin. All
cell lines were veriﬁed by STR proﬁling (Promega Gene-
Print 10) at the CRUK Beatson Institute. Cells were tested
for mycoplasma every second week. Cell survival was
assessed by MTT assay42 and by ﬂow cytometry following
staining with Zombie Violet membrane-impermeable
ﬂuorescent dye (Biolegend, London, UK).
The Ad5 vector, dl922-947, has been described pre-
viously. It contains a 24-bp deletion in E1A CR2 as well as
a 745-bp deletion in E3B. The Adenovirus Death Protein
(E3 11.6K) is retained43. Adenoviruses type 5, 11 and 35
were obtained from Dr H Wang, Barts Cancer Institute,
London, UK. Virus replication was assessed by TCID50
assay as previously1.
HeLa RIPK3 and control (LZRS) cells were generated by
retrovirus transduction of HeLa following transient
transfection of the plasmids pLZRS-RIPK3/pLZRS-con-
trol44,45 into Phoenix-AMPHO cells. Following selection
in zeocin, single-cell clones were isolated by dilution
cloning.
Necrosis induction and inhibition
Cells treated with TSZ (TNF-α (20 ng/ml), Smac-
mimetic (1 μM LCL-161) zVAD.fmk (25 µM)) for up to
72 h. Necrostatin-1 and NSA were obtained from Enzo Life
(see ﬁgure on previous page)
Fig. 5 RIPK3 expression augments dl922-947-induced cytotoxicity in vivo. a Expression of RIPK3 does not alter subcutaneous growth of HeLa
tumours in female nude mice (N = 14 for LZRS, 28 for RIPK3). Data represent mean ± SEM. b HeLa-RIPK3 tumours retain expression of RIPK3 by qRT-
PCR (left) and immunoblot (right). c HeLa-RIPK3 (clones D2 and E4) and HeLa-LZRS tumours were injected with a single intratumoural dose of dl922-
947 (5 × 109 particles) and harvested 48 h later. Expression of E1A and Ad5 proteins was assessed by quantitative IHC. d Necrotic area was quantiﬁed
using Slidepath Tissue Image Analysis. *p < 0.05. e HeLa-RIPK3 (clone D2) and HeLa-LZRS tumours were grown subcutaneously in CD1 female nude
mice (n = 12 per genotype). Once tumours reached approximately 200 mm3 (median 195mm3 for LZRS, 185 mm3 for RIPK3), mice were randomly
allocated to receive two doses of intratumoural dl922-947 (5 × 109 particles) or PBS, 14 days apart. Tumours were measured twice weekly by callipers.
Error bars represent SEM. *p < 0.05
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Sciences, Switzerland and Calbiochem, USA, respectively.
Speciﬁc RIPK1 (GSK3002962A, GSK3002963A) and RIPK3
(GSK2791840B) inhibitors were kind gifts from Dr Peter
Gough, GlaxoSmithKline (Collegeville, PA, USA).
Immunoblotting and co-immunoprecipitation
Twenty micrograms of total protein was electro-
phoresed at 140 V for 1 h, transferred onto nitrocellulose
and blocked in 5% non-fat milk. A full list of antibodies is
given in Supplementary Material. Membranes were
exposed on a Chemi-doc MP (Biorad) with ECL (GE
Healthcare, UK). RIPK3 expression was quantiﬁed using
ImageJ (NIH, v1.46r).
For co-immunoprecipitation, cells were lysed in Non-
idet P-40 buffer (10 mM Tris pH 8.0, 150mM NaCl, 1%
Nonidet P-40) with protease and phosphatase inhibitor
cocktail 2 (Sigma-Aldrich, UK). One milligram of total
protein was incubated overnight at 4° C with anti RIPK3
Ab (Santa-Cruz Sc374639, 1:50). Samples were incubated
for 2 h with 15 μl Dynabead Pan Mouse IgG magnetic
beads (Invitrogen, UK) and washed three times in ice-cold
Nonidet P-40 buffer. To pull down the desired complex,
16 μl of water and 4 μl of 5x Laemmli buffer were added to
the beads, vortexed and denatured at 95° C for 5 min.
Beads were removed and the samples were electro-
phoresed as above.
Electron microscopy
Cells grown on Thermanox coverslips were washed in
phosphate-buffered saline (PBS) before ﬁxing in 1.5%
Glutaraldehyde/0.1 M Sodium Cacodylate buffer for 1 h at
4° C and then washed three times for 5 min each in 0.1M
Sodium Cacodylate buffer rinse (2% sucrose). Samples
were postﬁxed in 1% Osmium Tetroxide/0.1 M Sodium
Cacodylate buffer for 1 h and then washed for 3× 10 min
in distilled water followed by en block staining in 0.5%
aqueous Uranyl Acetate for 1 h in the dark and washed
again twice for 1 min with dH2O. Samples were
dehydrated through a graded ethanol series (30, 50, 70,
90%) for 10 min followed by 100% ethanol 4× 5min,
followed with Propylene Oxide 3× 5min and then 1:1
Propylene Oxide: Araldite/Epon resin (TAAB 812) over-
night. Samples were then put into fresh pure Epon/Ara-
ldite resin, embedded in ﬂat bed moulds and polymerized
for 48 h at 60° C. Ultrathin sections (60–70 nm) were
produced using a LEICA Ultracut UCT (Leica Micro-
systems, UK) and Diatome diamond knife (Diatome,
USA) at an angle of 6 degrees. Sample sections were
picked up on 100 mesh formvar-coated copper grids and
then contrast stained with 2% Methanolic Uranyl Acetate
for 5 min followed by Reynolds Lead Citrate for 5 min.
Samples were viewed on a FEI Tecnai T20 (Zeiss, UK) at
an accelerating voltage of 200 kV, and images were cap-
tured using the GATAM Digital Imaging system.
Confocal microscopy
Cells were seeded on coverslips, infected with dl922-947
(MOI 1, 48 h), permeabilised with 0.2% Triton X-100
(Sigma) in PBS for 1 min and then ﬁxed in 4% paraf-
ormaldehyde for 10min. Cells were stained with anti-
MLKL antibody (Millipore, Watford, UK) and co-stained
with anti-phalloidin (Santa Cruz, CA, USA) antibody for
1 h at room temperature. Secondary antibodies were
incubated for 1 h in the dark at room temperature. Cells
were co-stained with 4,6-diamidino-2-phenylindole.
Coverslips were mounted on slides and images were
captured using a Zeiss 710 confocal microscope.
CRISPR/Cas9 gene editing
Two open-access software programs, CHOPCHOP
(https://chopchop.rc.fas.harvard.edu/) and CRISPR design
(http://crispr.mit.edu/), were used to design guide RNAs
(gRNA) targeted to MLKL exon 5. Three guides were
designed, although only one guide, which targeted the
RIPK3 phosphothreonine target site of MLKL (nt 25408-
25437 inclusive), yielded knockout clones. Annealed
(see ﬁgure on previous page)
Fig. 6 Caspase-8 inhibition augments viral cytotoxicity that is reversed by RIPK3 inhibition and MLKL knockout. a TOV21G cells were
infected with dl922-947 (MOI 0.001–100 pfu/cell). zVAD.fmk (25 µM) or DMSO was added 2 h postinfection. Cell survival was assessed 120 h
postinfection. b TOV21G cells were infected with dl922-947 (MOI 0.01–1 pfu/cell). zVAD.fmk (25 µM), zIETD.fmk (25 µM) or DMSO was added 2 h
postinfection. Cell survival was assessed 120 h postinfection. c MLKL phosphorylation was assessed in TOV21G following treatment with dl922-947
(MOI 1, 72 h) and/or zVAD.fmk (25 µM, 72 h) by immunoblot. d TOV21G cells were infected with dl922-947 (MOI 0.001–1). zVAD.fmk (25 µM) with or
without GSK2791840B (10 µM) was added 2 h later. Cell survival was assessed 120 h postinfection by MTT assay. e, f HeLa-RIPK3 D2 cells were infected
with dl922-947 (MOI 1) for up to 48 h or treated with TSZ for up to 2 h. RIPK3 was immunoprecipitated as described in Materials and Methods. RIPK3
and MLKL e and adenovirus proteins f were assessed in lysate and precipitate by immunoblot. Arrow in e represents MLKL band at 54 Kda. Asterisks
indicates non-speciﬁc band. g Single-cell TOV21G clones were isolated following CRISPR/Cas9-mediated MLKL exon 5 editing. MLKL expression was
assessed by immunoblot (left). Clones marked asterisk (F9, E8, D6) had reduced MLKL expression and demonstrated mono-allelic deletions in exon 5
by sequencing. MLKL+/− clones had reduced sensitivity to TSZ-induced necrosis (right). h No difference in dl922-947 sensitivity in MLKL+/− clones
compared to MLKL+/+. Each dot represents IC50 for one clone from a triplicate dose–response experiment. i Loss of MLKL reverses zVAD.fmk-induced
enhancement of dl922-947 cytotoxicity. Each point represents a single triplicate experiment at each MOI. **p < 0.01. ***p < 0.001. Concentration of
zVAD.fmk was 25 µM
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oligonucleotides were ligated into BbsI-linearised
pSpCas9(BB)-2A-Puro (PX459 v2—Addgene no.
6298846, a gift from Feng Zhang via Addgene). All plas-
mids were sequenced to conﬁrm successful ligation.
TOV21G cells (4× 105) were plated overnight in
antibiotic-free medium and transfected with 4 µg PX459
using Lipofectamine 2000, selected under puromycin (2.5
µg/ml) for 48 h and plated onto 96-well plates (10 cells/
ml). Single-cell colonies were expanded for DNA extrac-
tion, protein extraction and cryopreservation.
PCR primers spanning potential sites of deletion were
designed (Forward 5ʹ-ACAATCCCTGCCCTTTACTCC-
3ʹ, Reverse 5ʹ-GAGTTTAGGTGGTCCTTGGAGG-3ʹ).
Clones with large PCR insertion/deletions were selected
for subsequent analysis. Remaining clones were screened
using the Surveyor Nuclease Assay (Integrated DNA
Technology). Mutations were conﬁrmed by Sanger
sequencing. All sequence alignment was performed using
MAFFT version 7 (http://mafft.cbrc.jp/).
In vivo experiments
All animal experiments were performed in the Cancer
Research UK Beatson Institute Biological Services Unit
(registered facility 60/2607) under appropriate UK Home
Ofﬁce personal and project licence (70/8645) authority.
All experiments adhered to NCRI Guidelines on the use
Fig. 7 Schematic representation of adenovirus-induced cell death. a In cells lacking RIPK3 (or expressing low levels of RIPK3), adenovirus
infection induces cell death that resembles necrosis but is TNF-α, RIPK1, RIPK3 and MLKL independent and is not apoptotic. b In the presence of
RIPK3, either endogenous or via overexpression, cells undergo RIPK1- and MLKL-independent cell death that is partially RIPK3 dependent. c In
TOV21G cells, adenovirus infection leads to formation of a complex containing RIPK3, MLKL and viral protein(s). In the presence of either zVAD.fmk or
zIETD.fmk, inhibition of caspase-8 leads to MLKL phosphorylation and necrotic cell death that is both RIPK3 and MLKL dependent
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of animals in medical research47. Animals were allocated
treatment randomly by cage. All injections and tumour
measurements, as well as all decisions about animal wel-
fare, were taken by BSU staff and D.A. to prevent bias.
Female CD1 nu/nu mice were injected subcutaneously
with 5× 106 cells in 100 μl of PBS in groups of 6.
Tumours were measured three times a week, and volume
was calculated using the equation (L×W2)/2, where L=
longest diameter and W= perpendicular width. Once
tumours reached approximately 200 mm3, each group
received intratumoural doses of dl922-947 (5× 109 par-
ticles in 30 µl) or PBS (30 µl). For tumour IHC and
immunoblot experiments (Fig. 5b – d), both HeLa RIPK3
D2 and HeLa RIPK3 E4 tumours were used. Tumours
were harvested 48 h after single injection of dl922-947
(5× 109 particles) or PBS and cut into two equal parts.
One was snap frozen and the other ﬁxed overnight in 10%
paraformaldehyde before processing. Slides were stained
for the expression of E1A (rabbit anti Ad2/5 E1A, sc-430,
1:50, Santa-Cruz, CA) or adenovirus structural proteins
(goat anti-adenovirus, ab36851, 1:400, Abcam, UK).
Stained slides were digitised (Hamamatsu NanoZoomer
NDP, Hamamatsu Photonics, Welwyn Garden City, UK)
and viewed using Slidepath Digital Image Hub V4.0.7
(Leica Microsystems, Milton Keynes, UK). Areas of
tumour were identiﬁed and scored using Slidepath Tissue
Image Analysis and histoscores were generated by mul-
tiplying intensity of cellular staining within marked areas
(range 0–3) by the percentage of cells with positive
staining (range 0–100), with a maximum histoscore of
300. Tumour necrotic area was calculated as the per-
centage of acellular/anuclear area per tumour divided by
total tumour area using Slidepath Tissue Image Analysis.
In the therapeutic experiment (Fig. 5e), HeLa RIPK3 D2
cells were utilised and two doses of virus were adminis-
tered, 14 days apart (days 23 and 37 for LZRS tumours;
days 27 and 41 for RIPK3). Mice were killed when
tumours reached clinical end point (maximum length
15mm or tumour ulceration).
Statistics
All data points show mean± SD unless otherwise sta-
ted. All statistical calculations were performed using
Prism (v6, GraphPad, CA). All comparisons utilise
unpaired t-test unless otherwise stated. p< 0.05 was
considered signiﬁcant.
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